Sonia Soto-Schütte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sonia Soto-Schütte has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Gutiérrez-Calvo
Hospital Universitario Príncipe de Asturias, General and Digestive Surgery Department, Alcalá de Henares, Spain
4 shared publications - Belén Matías-García
General Surgery, Príncipe de Asturias Teaching Hospital, Alcalá de Henares, ESP
4 shared publications - Enrique Ovejero-Merino
Hospital Universitario Príncipe de Asturias, General and Digestive Surgery Department, Alcalá de Henares, Spain
4 shared publications - Ana Quiroga-Valcárcel
Hospital Universitario Príncipe de Asturias, General and Digestive Surgery Department, Alcalá de Henares, Spain
3 shared publications - Cristina Vera-Mansilla
General Surgery Department. University Hospital of Príncipe de Asturias. Alcalá de Henares, Madrid. Spain
3 shared publications Eduardo Serrano-Yébenes
Hospital Universitario Príncipe de Asturias, Servicio de Cirugía General y del Aparato Digestivo, Alcalá de Henares, Spain
3 shared publications
Latest Publications
- 24 February 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (2) , e129-e130
Survival analysis and disease-free survival in pancreatic neuroendocrine tumors. Experience in a single center.
- 24 February 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (2) , e129-e130
Survival analysis and disease-free survival in pancreatic neuroendocrine tumors. Experience in a single center.
- 24 February 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (2) , e104
Does the extent of lymphadenectomy and the presence of positive lymphadenopathy influence survival and disease-free interval after left hemicolectomy?
- 24 February 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (2) , e104
Does the extent of lymphadenectomy and the presence of positive lymphadenopathy influence survival and disease-free interval after left hemicolectomy?
- 24 February 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (2) , e103
Risk factors for anastomotic leakage after total colectomy in patients with colorectal carcinoma.
- 24 February 2022
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 48 (2) , e103
Risk factors for anastomotic leakage after total colectomy in patients with colorectal carcinoma.
- Open Access
- 13 September 2021
- Published by Hindawi Limited in International Journal of Surgical Oncology
- Vol. 2021, 1-9
Prognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma
Objective. The main objective of the study was to determine the effect of the presence of mutation in the KRAS gene on the survival in patients with colorectal cancer (CRC) and peritoneal metastases (PM). Materials and Methods. A retrospective cohort study was performed. Patients diagnosed with CRC with synchronous or metachronous PM between January 2006 and December 2019 were included. Data on the histopathological, clinical, and treatment factors were collected. The effect of each variable on survival was evaluated by Cox regression. Results. A total of 149 patients were included (64 women (43%) and 85 men (57%); mean age, 63 years). The long-term survival rate at 36 months was 24% (median, 21 months). KRAS mutation was detected in 75 patients (50.3%). Kaplan–Meier analysis estimated that likelihood of survival was higher in patients with wild-type KRAS tumours (35%) than in mutated-type KRAS (14%) (median: 28 vs. 15, respectively) ( P = 0.001 ). Within the categories into which the peritoneal cancer index (PCI) was classified, survival at 36 months depended on the KRAS status. Survival in wild-type KRAS tumours with PCI 1–10 was 71% and with PCI 11–20 was 26%, while in mutant-type KRAS tumours, survival was 41% and 4%, respectively ( P = 0.025 ). In the multiple regression analysis, the KRAS mutation was revealed to have an independent prognostic value (HR: 2.144; 95% CI: 1.342–3.424). Conclusion. The mutational status of the KRAS gene has demonstrated a strong association with survival and prognostic utility in patients with CRC with PM.
- 13 September 2021
- Published by Hindawi Limited in International Journal of Surgical Oncology
- Vol. 2021, 1-9
Open AccessPrognostic Value of KRAS Gene Mutation on Survival of Patients with Peritoneal Metastases of Colorectal Adenocarcinoma
Objective. The main objective of the study was to determine the effect of the presence of mutation in the KRAS gene on the survival in patients with colorectal cancer (CRC) and peritoneal metastases (PM). Materials and Methods. A retrospective cohort study was performed. Patients diagnosed with CRC with synchronous or metachronous PM between January 2006 and December 2019 were included. Data on the histopathological, clinical, and treatment factors were collected. The effect of each variable on survival was evaluated by Cox regression. Results. A total of 149 patients were included (64 women (43%) and 85 men (57%); mean age, 63 years). The long-term survival rate at 36 months was 24% (median, 21 months). KRAS mutation was detected in 75 patients (50.3%). Kaplan–Meier analysis estimated that likelihood of survival was higher in patients with wild-type KRAS tumours (35%) than in mutated-type KRAS (14%) (median: 28 vs. 15, respectively) ( P = 0.001 ). Within the categories into which the peritoneal cancer index (PCI) was classified, survival at 36 months depended on the KRAS status. Survival in wild-type KRAS tumours with PCI 1–10 was 71% and with PCI 11–20 was 26%, while in mutant-type KRAS tumours, survival was 41% and 4%, respectively ( P = 0.025 ). In the multiple regression analysis, the KRAS mutation was revealed to have an independent prognostic value (HR: 2.144; 95% CI: 1.342–3.424). Conclusion. The mutational status of the KRAS gene has demonstrated a strong association with survival and prognostic utility in patients with CRC with PM.